Cyclopamine

目录号:S1146 别名: 11-deoxojervine

Cyclopamine Chemical Structure

Molecular Weight(MW): 411.62

Cyclopamine是一种特异性Hedgehog (Hh)信号通路拮抗剂,作用于Smoothened (Smo),在TM3Hh12细胞中IC50为46 nM。

规格 价格 库存 购买数量  
RMB 1227.56 现货
RMB 2188.93 现货
RMB 3037.37 现货
RMB 3833.48 现货
有超大折扣

今日订购,明日送达,全国免运费!

全国免费电话:400-668-6834   |   Email:info@selleck.cn

客户使用该产品的4个实验数据:

  • (A) The effects of cyclopamine (10 μM) in pancreatic cancer cell invasion. The number of migrated cells was quantified by counting the number of cells from 10 random fields at 200 magnification. (B) The effects of cyclopamine on the expression of EMT-related molecules E-cadherin and vimentin, and Hh pathway-related proteins SMO and Gli-1 were analyzed by Western blotting following treatment of MiaPaCa-2 and Panc-1 with SDF-1 for 48 h in the presence or absence of the SMO inhibitor cyclopamine. Normal culture was used as a negative control. (C) The EMT-related molecules Ecadherin and vimentin mRNA levels, and Hh pathway-related genes at mRNA level were analyzed by real-time RT-PCR following treatment of MiaPaCa-2 and Panc-1 with SDF-1 for 48 h in the presence or absence of the SMO inhibitor Cyclopamine. Normal culture was used as a negative control.

    Cancer Lett 2012 322, 169-176. Cyclopamine purchased from Selleck.

    (A)[3H]thymidine incorporation assay of B16F10 melanoma cells treated with DMSO or cyclopamine after incubation with SA-CM from WT and Cav1KO dermal fibroblasts. Representative phase-contrast images of B16F10 cells treated with SA-CM from WT and Cav1KO fibroblasts with cyclopamine are shown on the right. Similar experiments (B) were done with A-375 cells incubated with SA-CM from hTBJ1-shCtrl and hTBJ1-shCAV1 cells.

    Cancer Res 2012 72, 2262-74. Cyclopamine purchased from Selleck.

  • (A) Exogenous Shh peptide (500 ng/mL) for 72 hours promoted expansion of CD34+ cells and CD34- cells, cyclopamine (10 μM) for 72 hours induced apoptosis of CD34+ cells and CD34- cells, as measured by 3-(3,5-dimethylthiazol-2-yl)-2,5-diphenyl-tetrazoliumbromide (MTT) assay, n =4, bars, standard deviation. *Statistically significant compared with CD34+ cells. (B) Exogenous Shh peptide (500 ng/mL) promoted cell expansion after 48 hours and cyclopamine (10 μM) induced cell apoptosis within 24 hours measured by MTT assay (n=6).

    Exp Hematol 2012 40, 418-27. Cyclopamine purchased from Selleck.

    For MTT assays, cells (2,000 ~ 5,000 cells/well) were subcultured into 96-well plates according to their growth properties. Cell proliferation was assayed at 72 hr after treatment of Cyclopamine by adding 20 μl of 5 mg/ml 3-(4,5-Dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT) solution per 100 μl of growth medium. After incubating for 3-4 h at 37°C, the media were removed and 150 µl/well of MTT solvent (either absolute DMSO or isopropanol containing 4 mM HCl and 0.1% Nonidet-40) was added to dissolve the formazan. The absorbance of each well was measured by ELx808 (BioTek, Winooski, VT) or Wallac Victor2 (Perkin-Elmer Life Sciences, Boston, MA) Microplate Reader. Viable cells are presented as percent of control, vehicle-treated cells.

     

     

    Dr. Yong-Weon Yi from Georgetown University Medical Center. Cyclopamine purchased from Selleck.

产品安全说明书

Hedgehog/Smoothened抑制剂选择性比较

生物活性

产品描述 Cyclopamine是一种特异性Hedgehog (Hh)信号通路拮抗剂,作用于Smoothened (Smo),在TM3Hh12细胞中IC50为46 nM。
靶点
Smoothened [1]
(TM3Hh12 cells)
46 nM
体外研究

Cyclopamine 抑制Hedgehog信号通路, IC50 为46 nM, 且在[3H]Hh-Ag结合实验中,作用于CHO-K1细胞,抑制人类Smo受体活性,IC50为 280 nM。[1] Cyclopamine作用于表达Patched (PTCH) mRNA的肠源性肿瘤细胞,显著抑制 Hedgehog通路活性,这种作用存在剂量依赖性,且浓度为3 μM时,抑制肿瘤细胞生长,抑制达75-95%, 但是作用于不表达PTCH mRNA的结肠癌细胞没有效果,说明Cyclopamine 特定作用于Hedgehog 通路,且没有毒性。[2]通过与Smo直接作用而抑制Hedgehog信号,Cyclopamine (10 μM) 抑制SMOhigh Cyclopamine-反应细胞系L3.6sl和 Panc 05.04增殖,抑制达 75-80%,且使凋亡率提高2.5到 3.5倍,但是不影响BxPC3-SMOlow 细胞系。[3] Cyclopamine 处理E3LZ10.7细胞系,显著降低Snail mRNA,且提供E-钙粘着蛋白转录。Cyclopamine处理Hedgehog依赖型 L3.6pl 细胞,显著抑制浸润型细胞, 使转移细胞降低500多倍,但是对Hedgehog非依赖性细胞系Panc-1没有影响。[4]

Cell Data
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID
OS-RC-2 MX7Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MUjJR|UxRTVwOE[2OkDPxE1? M1zPfHNCVkeHUh?=
DOHH-2 M1OxdGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NXnqT5hPUUN3ME25MlM2Pjh7IN88US=> MYPTRW5ITVJ?
no-10 Mli3S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M2jaW2lEPTB;OT65NFM6KM7:TR?= MlS3V2FPT0WU
LS-513 NH7tfZJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MW\JR|UxRTFzLkO1OFch|ryP NXzoSoNFW0GQR1XS
ALL-PO MW\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NIXqcFJKSzVyPUGxMlc4OzRizszN NF65ellUSU6JRWK=
8-MG-BA MnPES5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NYrkN4NuUUN3ME2xN{4yOTJ|IN88US=> NGjJdotUSU6JRWK=
RPMI-8402 Mmf2S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MoDxTWM2OD1zNT64OVM4KM7:TR?= M4LzdnNCVkeHUh?=
EoL-1-cell NELVPY5Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NHHsSVNKSzVyPUG4MlU6PDhizszN MXrTRW5ITVJ?
NALM-6 NXraUYxsT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NFrCeGNKSzVyPUG5MlAyPjdizszN NEHPdm1USU6JRWK=
DEL NVP1OWJ2T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MY\JR|UxRTJyLkG0O|Eh|ryP MlvmV2FPT0WU
SR MlfzS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NFm1ToxKSzVyPUKzMlY4OTVizszN M1O2cnNCVkeHUh?=
697 MVLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MUPJR|UxRTJ4Lk[xOVUh|ryP NX2yR3luW0GQR1XS
COLO-829 NGK2e4NIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MX;JR|UxRTJ4Lki0PFMh|ryP MVjTRW5ITVJ?
EVSA-T M4fDRWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MkPOTWM2OD1{Nz61OVYyKM7:TR?= MVPTRW5ITVJ?
ATN-1 NIT4cmFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= Ml65TWM2OD1|MT6yN|I6KM7:TR?= NUDqOWd5W0GQR1XS
L-363 M2rSN2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MmDCTWM2OD1|MT63OFYyKM7:TR?= MkftV2FPT0WU
LAMA-84 NXLvR4VsT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NHz2Z4ZKSzVyPUOyMlUzOTFizszN MnLUV2FPT0WU
NOS-1 M4\T[Wdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M{nuXGlEPTB;M{SuNlk2PiEQvF2= NWrDNXg4W0GQR1XS
BB30-HNC Mmi2S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NW\YbIZsUUN3ME2zOE4{OzB4IN88US=> MmryV2FPT0WU
BC-1 MWTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? Mo[xTWM2OD1|Nz65O|Q3KM7:TR?= NWPpdpp6W0GQR1XS
IST-SL2 NH;pb4xIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MVPJR|UxRTN6LkKyOEDPxE1? NXvVfXdDW0GQR1XS
D-392MG MYjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MmnFTWM2OD12MD6yNlE2KM7:TR?= NGfpSJVUSU6JRWK=
no-11 MlLNS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NYfCe3poUUN3ME20NE42PTJzIN88US=> M1fqWXNCVkeHUh?=
LC4-1 NUO0R5dnT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NYewXYRXUUN3ME20NE45PzF4IN88US=> NUXreldNW0GQR1XS
A388 MlO3S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NX20fJJvUUN3ME20Nk42QDR6IN88US=> NXj1NJBRW0GQR1XS
NTERA-S-cl-D1 MlnJS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M2\jfWlEPTB;NEKuO|A4PCEQvF2= M1Xye3NCVkeHUh?=
CESS NGjneZRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M{LmTWlEPTB;NESuNlI{OiEQvF2= M3;MZXNCVkeHUh?=
RS4-11 M1f3Vmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M2K3UGlEPTB;NEmuNFk{QCEQvF2= M2qwfXNCVkeHUh?=
MS-1 M3q5Tmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M1rVcGlEPTB;NUCuPVM2OSEQvF2= NWLxVmRHW0GQR1XS
CTV-1 NGnTRnhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MVfJR|UxRTVzLkC3OEDPxE1? MWnTRW5ITVJ?
D-502MG M4DaV2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NYC5cWJJUUN3ME21NU43OjdzIN88US=> MlTFV2FPT0WU
ML-2 Mn3XS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MnjyTWM2OD13Mj65NVk2KM7:TR?= NYC0WFVFW0GQR1XS
SK-NEP-1 MmjCS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MUPJR|UxRTV|LkO5NlMh|ryP NXrkOHA2W0GQR1XS
LOXIMVI M2XRVWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M1jYVGlEPTB;NUOuOVg5PCEQvF2= NGPNcGdUSU6JRWK=
DJM-1 MkOyS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MWHJR|UxRTV4LkOzPVEh|ryP M{npVXNCVkeHUh?=
GI-1 M4DWeWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MkfBTWM2OD13Nj62NVQ6KM7:TR?= NUfMUm51W0GQR1XS
IST-MES1 MUXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? Ml3kTWM2OD14MD61OFk{KM7:TR?= NFPwOpBUSU6JRWK=
MV-4-11 MXLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NULvdIY5UUN3ME22NE43PTN6IN88US=> NF;EV5BUSU6JRWK=
OVCAR-4 NIjT[oxIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= Mki5TWM2OD14Mz61OlU4KM7:TR?= NYTUR4R4W0GQR1XS
KE-37 MYDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M2HkeGlEPTB;Nk[uNlY3QCEQvF2= MlvOV2FPT0WU
D-542MG NIL3PIdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M1iwVGlEPTB;NkiuOFE{PSEQvF2= Ml7GV2FPT0WU
MHH-PREB-1 NEWxOWJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MVLJR|UxRTd{Lki0OFEh|ryP MmHXV2FPT0WU
MRK-nu-1 NXrRbYhjT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M2XhZmlEPTB;N{OuOFcxPSEQvF2= NVryTINFW0GQR1XS
D-247MG MXPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MV7JR|UxRTd|LkW0OFIh|ryP M{XXN3NCVkeHUh?=
OCI-AML2 NELueJZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MXPJR|UxRTd4LkmzOlkh|ryP MXjTRW5ITVJ?
LP-1 M37VbGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MoDmTWM2OD16Mj64O|MyKM7:TR?= MlTwV2FPT0WU
HCC1599 M{PrUmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M2XIUmlEPTB;OESuNlg{PyEQvF2= MV3TRW5ITVJ?
KARPAS-45 MVXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NYXyZVdKUUN3ME24OE43QTl{IN88US=> NIDN[GRUSU6JRWK=
BE-13 NYruTGhwT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MUTJR|UxRTl7LkC0O|ch|ryP M3O0OXNCVkeHUh?=
GCIY M1vPdmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NXLJXHg{UUN3ME25PU4xQTV2IN88US=> M1PIN3NCVkeHUh?=
BV-173 M3fs[Wdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 Mlm5TWM2OD1zMECuN|I2KM7:TR?= MmPvV2FPT0WU
LB2518-MEL MX\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MWTJR|UxRTFyMD63PFkh|ryP MVnTRW5ITVJ?
KS-1 NEHGfnZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NYTrV|liUUN3ME2xNFEvPjN7IN88US=> NWnMdW15W0GQR1XS
MOLT-16 MW\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NEHWZ41KSzVyPUGwOE46QDZizszN M3L4XHNCVkeHUh?=
NCI-H1770 MV;Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MXXJR|UxRTFyOD63PFQh|ryP M4XISXNCVkeHUh?=
NCI-H82 MX\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M4DrcGlEPTB;MUGwMlk4PiEQvF2= MkK5V2FPT0WU
NCCIT NXL1cYNVT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MYXJR|UxRTFzMj61Nlkh|ryP M3vNWHNCVkeHUh?=
KALS-1 NFu3VIZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MVHJR|UxRTFzNT65OFEh|ryP MnrZV2FPT0WU
LB2241-RCC M1HyS2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NWLMTpM4UUN3ME2xNVYvPjd7IN88US=> M{\ZWXNCVkeHUh?=
HH NH3McWdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M33LU2lEPTB;MUG3MlM6PSEQvF2= Ml3SV2FPT0WU
HD-MY-Z Mme3S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NILIeWxKSzVyPUGxPE41QDhizszN MmXMV2FPT0WU
EB-3 NXLodGk{T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NV;rSnJ7UUN3ME2xNlMvODl2IN88US=> MonFV2FPT0WU
BL-70 MoTMS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MkXyTWM2OD1zMkOuNVI4KM7:TR?= MnLYV2FPT0WU
K-562 M{TSXGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NEL0dWlKSzVyPUGyOk4zPDVizszN NV\ZRYh1W0GQR1XS
HT-144 MlrYS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NIXPZlhKSzVyPUGzN{4yPjRizszN MWXTRW5ITVJ?
PF-382 NG\rNpZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NYftcYtUUUN3ME2xN|QvOzZzIN88US=> MYfTRW5ITVJ?
RPMI-8226 MmTTS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NFjKXWpKSzVyPUGzOU4xPDVizszN M3nrTHNCVkeHUh?=
NCI-H1355 MVvHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NEizbGZKSzVyPUGzOU42QDdizszN NHL3ZXFUSU6JRWK=
LXF-289 NXjm[I14T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MVXJR|UxRTF|OT63PFEh|ryP Ml[xV2FPT0WU
NCI-H69 NYjVdZRKT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MXjJR|UxRTF2Mj65N|Ih|ryP NIrLSXZUSU6JRWK=
SK-MEL-1 M373Zmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 Mk\JTWM2OD1zNEeuNVMh|ryP Moq3V2FPT0WU
KARPAS-299 MoC4S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M33ZSmlEPTB;MUS5MlEzKM7:TR?= MUnTRW5ITVJ?
GB-1 NH3SOVVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NFro[WRKSzVyPUG0PU4{OjJizszN MVfTRW5ITVJ?
CMK MoHTS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NGTlV2RKSzVyPUG0PU42OTVizszN MnrpV2FPT0WU
MPP-89 NE\GZmpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MXjJR|UxRTF3Nj6wN|Uh|ryP NXW5PWZVW0GQR1XS
KU812 NXnHZ5VZT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NX3H[og2UUN3ME2xOlEvQTB{IN88US=> NEji[ZNUSU6JRWK=
REH MnKyS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M3TES2lEPTB;MU[yMlEzPSEQvF2= MYrTRW5ITVJ?
NEC8 MYLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NH\C[XVKSzVyPUG2OU4xOjZizszN MlniV2FPT0WU
KP-N-YS M{HSWGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 Mn\LTWM2OD1zNkiuN|k2KM7:TR?= MXzTRW5ITVJ?
Ramos-2G6-4C10 M1\qRmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 Mnf4TWM2OD1zNkmuPVE2KM7:TR?= NEHqW4lUSU6JRWK=
Becker NYnFPXVKT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MlznTWM2OD1zN{SuNVgh|ryP MlfxV2FPT0WU
LB647-SCLC MnzDS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NYruNG9UUUN3ME2xO|UvQDR3IN88US=> MnPSV2FPT0WU
LU-139 M2q0TGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MXPJR|UxRTF5OD6wNVkh|ryP NYKyNGxXW0GQR1XS
QIMR-WIL NYPoPXR3T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MWDJR|UxRTF5OT62OFYh|ryP MV\TRW5ITVJ?
NCI-H1395 NEjIUpZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MoOyTWM2OD1zN{muPVk3KM7:TR?= MWDTRW5ITVJ?
NOMO-1 MYfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M2L2WmlEPTB;MUiyMlg2KM7:TR?= M1PGfXNCVkeHUh?=
GI-ME-N MXLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NFj0bXFKSzVyPUG4O{46PjlizszN NWOybVdDW0GQR1XS
KMS-12-PE MnvxS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MYrJR|UxRTF6OT6yO|Mh|ryP MULTRW5ITVJ?
Daudi NIHwfJpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MmTmTWM2OD1zOUGuNVI5KM7:TR?= NEnCOW1USU6JRWK=
LB996-RCC NHT3V5FIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= Mn\WTWM2OD1zOUGuOlk6KM7:TR?= Mm\mV2FPT0WU
NCI-H2107 M1nnXmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MXrJR|UxRTF7Mz63N|kh|ryP M3v2cHNCVkeHUh?=
SK-PN-DW MU\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NX;BeWNrUUN3ME2xPVQvPzF7IN88US=> MnLuV2FPT0WU
MC-CAR NYC4O5pUT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M{DrV2lEPTB;MkCyMlI2OyEQvF2= NUfMfoJPW0GQR1XS
SNB75 M4rlfmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M3zPWWlEPTB;MkKxMlk1KM7:TR?= MXPTRW5ITVJ?
ES4 M{D1Zmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MV\JR|UxRTJ{Mz63PFMh|ryP MUTTRW5ITVJ?
KARPAS-422 NGjEfWlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NFnUNYxKSzVyPUKyPE4{PTJizszN NIrES|dUSU6JRWK=
NCI-H1648 MljRS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NFHB[3ZKSzVyPUKyPU41QDlizszN NEP6Vm1USU6JRWK=
ES6 M2PrOGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NFGzNlBKSzVyPUKzPU41OyEQvF2= MVfTRW5ITVJ?
KNS-81-FD NVrqXm5rT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MoTCTWM2OD1{NEGuNVk4KM7:TR?= M1XXSXNCVkeHUh?=
JAR MUDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MYHJR|UxRTJ3Nj6yNlUh|ryP M3vUU3NCVkeHUh?=
NB1 NETERmJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MWPJR|UxRTJ4MD61NVYh|ryP MofqV2FPT0WU
D-336MG NEjGdpZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NWTJcmlkUUN3ME2yOlAvPjl6IN88US=> NIrvdGFUSU6JRWK=
BC-3 M4DTcmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 Mn3ZTWM2OD1{NkWuNVc5KM7:TR?= NF\tUoFUSU6JRWK=
HCC2218 MoLpS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NYPVeWdJUUN3ME2yOlYvPDF3IN88US=> M3\GW3NCVkeHUh?=
TE-9 NETmfYZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NHW3TG1KSzVyPUK2Ok43OjdizszN NVrCXpptW0GQR1XS
LB1047-RCC MUHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NHf0T5JKSzVyPUK2Ok44PTNizszN M1LYWHNCVkeHUh?=
CTB-1 MYLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MorsTWM2OD1{NkmuPVc{KM7:TR?= NVTGPHFuW0GQR1XS
NB7 MVPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MXLJR|UxRTJ5MTFOwG0> MlzVV2FPT0WU
ST486 NHHDdo5Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NYWxZVJoUUN3ME2yO|cvPDF{IN88US=> NHzIfWRUSU6JRWK=
HCC1187 NV3RO4RjT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M4HPbWlEPTB;MkiyMlgyOSEQvF2= NYfaRmhWW0GQR1XS
NCI-SNU-16 M4[z[2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NFnYTVVKSzVyPUK4OE4zPDhizszN M3jETHNCVkeHUh?=
COR-L279 NX;P[3pTT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NX;xdGpsUUN3ME2yPVEvPTh2IN88US=> MmfOV2FPT0WU
ES8 MUjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NUfjOXJJUUN3ME2yPVQvOTh{IN88US=> MnXqV2FPT0WU
U-698-M M3vHfGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MlftTWM2OD1{OUiuNlQ{KM7:TR?= M2HtSnNCVkeHUh?=
HEL NUPGeI42T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NGXXXnJKSzVyPUOwPU4yPDlizszN Mk\BV2FPT0WU
KINGS-1 MlvlS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M4jPdWlEPTB;M{GwMlY4PCEQvF2= NYHpTWR3W0GQR1XS
KY821 NUK5Vo1xT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NX25UI9QUUN3ME2zN|YvPTl3IN88US=> MYjTRW5ITVJ?
MZ1-PC Mn3sS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NIK0d5RKSzVyPUO0OU43OThizszN NX6zXJM1W0GQR1XS
LS-411N MlKxS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NEnlSW1KSzVyPUO1OE43PiEQvF2= MmX5V2FPT0WU
SIG-M5 M2nUNmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MXrJR|UxRTN3OT63PFIh|ryP M2jHOnNCVkeHUh?=
HT M{jCPGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MkT5TWM2OD1|NkeuO|EyKM7:TR?= NY\mZ3ROW0GQR1XS
HC-1 MkiyS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MULJR|UxRTN4Nz63PFch|ryP Ml3zV2FPT0WU
NCI-H1694 NVHLdnFwT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MmnsTWM2OD1|N{KuPVM1KM7:TR?= NWDr[4JmW0GQR1XS
BB65-RCC MYTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NEnhSFFKSzVyPUO3Ok4zPDVizszN M{O1XnNCVkeHUh?=
HAL-01 M1\ZR2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M4\6PGlEPTB;M{e5Mlg{QCEQvF2= MWHTRW5ITVJ?
ARH-77 NELQWmVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M{TDU2lEPTB;M{m0MlAxQCEQvF2= MlnSV2FPT0WU
MZ7-mel NIXT[5RIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MmPBTWM2OD1|OUeuNlM{KM7:TR?= NIHiZohUSU6JRWK=
SIMA NFLXSJRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= Ml\UTWM2OD12MEOuPVM{KM7:TR?= MnPuV2FPT0WU
DG-75 MlLuS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MWTJR|UxRTRzNT62PVgh|ryP NUPkR5VRW0GQR1XS
HUTU-80 M3uwb2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MUPJR|UxRTRzOT6xPFUh|ryP M3fQbHNCVkeHUh?=
KNS-42 M1LUN2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MUfJR|UxRTR{NT64NVUh|ryP NX;sWWZGW0GQR1XS
SH-4 MnvzS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M2XBRWlEPTB;NEK3MlU3PSEQvF2= Mn7ZV2FPT0WU
L-540 NILRfWxIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MYXJR|UxRTR|MT6wN|Eh|ryP NIf0OpdUSU6JRWK=
NB10 M2XPTmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MVjJR|UxRTR2MT6yN|Qh|ryP MV7TRW5ITVJ?
ES1 NHTsc4ZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M3\3bmlEPTB;NEWyMlc2OyEQvF2= NGrLfpRUSU6JRWK=
KMOE-2 MVHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NW\5NlVnUUN3ME20OVYvPzFzIN88US=> NVXnV4s{W0GQR1XS
MC116 M3fac2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M3X6W2lEPTB;NEW4MlEyPiEQvF2= MoXQV2FPT0WU
RCC10RGB MX7Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? Mo\vTWM2OD12NkCuNFA2KM7:TR?= NX7mZnBSW0GQR1XS
RL95-2 NXjP[ZZbT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NI\wfWhKSzVyPUS2NE4zOzdizszN MVPTRW5ITVJ?
Raji MmDBS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MoOyTWM2OD12NkiuNVQ{KM7:TR?= MWLTRW5ITVJ?
CAS-1 M131OWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M4ToW2lEPTB;NEeyMlA4OyEQvF2= MU\TRW5ITVJ?
Calu-6 M2exOmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NFPTcHdKSzVyPUS3OU4zPjVizszN MVnTRW5ITVJ?
KG-1 MUXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NUnYdXRxUUN3ME20O|gvPDRizszN NF33[5hUSU6JRWK=
LB771-HNC NH7PVGFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MYPJR|UxRTR6Mj6yN|Ih|ryP MVzTRW5ITVJ?
ACN MYLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NIq0b|lKSzVyPUS5N{42QTlizszN NUDocFhJW0GQR1XS
KM12 M3PESmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M3zwWWlEPTB;NEm2MlU5QSEQvF2= M{DKfHNCVkeHUh?=

... Click to View More Cell Line Experimental Data

体内研究 Cyclopamine 每天按50 mg/kg剂量处理小鼠,持续22天,消除HUCCT1移植瘤,且没有明显副作用。[2] Cyclopamine 按1.2 mg剂量处理Panc 05.04和 L3.6sl驱动的肿瘤7天,前者诱导明显的肿瘤细胞凋亡,后者降低肿瘤质量,降低达50-60%,但是作用于BxPC3-SMOlow肿瘤没有效果。[3] Cyclopamine单独处理E3LZ10.7 和L3.6pl移植瘤,显著抑制肿瘤转移,且和 Gemcitabine联用处理,完全废除转移。[4]

推荐的实验操作(此推荐来自于公开的文献所以Selleck并不保证其有效性)

激酶实验:[1]
+ 展开

激酶实验:

Gli-Luc实验测定Hh 信号通路末期, 即使用荧光素酶进行读数,测定Gli的转录调控。Cyclopamine 在DMSO中连续稀释用于实验,然后加到空的实验板上。TM3Hh12 细胞(TM3 细胞含Hh反应受体基因结构 pTA-8xGli-Luc) 悬浮在含5% FBS 和15 mM Hepes pH 7.3的F12 Ham’s/DMEM (1:1)培养基上, 加到实验板上,与Cyclopamine在37oC下温育30分钟左右。1 nM Hh-Ag 1.5 加到实验板上,然后在37oC下温育。48小时后,在实验板中加入Bright-Glo或MTS,然后在492 nm处测定发光度或吸光度。通过分析反应曲线,使用R统计软件包测定IC50值。
细胞实验:[2]
+ 展开
  • Cell lines: SEG1, OE33, KYAE, KYSE180, SNU1, AGS, SNU16, NCI-N-87, HUCCT1, PANC1, PL5, PL6, BXPC3, HS766T, KYSE150, GBD1, DLD1, 和HCT116
  • Concentrations: 溶于DMSO, 终浓度为3 μM
  • Incubation Time: 4天
  • Method: 在96孔板上,用Cyclopamine 处理细胞。通过MTS实验测定细胞活力。进行CellTiter96比色测定,进行2和4天,然后在490 nm处通过测定光密度而测定存活细胞。
    (Only for Reference)
动物实验:[2]
+ 展开
  • Animal Models: 皮下注射HUCCT1细胞的无胸腺裸鼠
  • Formulation: 溶于DMSO, 然后用盐水稀释
  • Dosages: 50 mg/kg/day
  • Administration: 皮下注射处理
    (Only for Reference)

溶解度 (25°C)

体外 DMF 10 mg/mL warmed (24.29 mM)
Ethanol 2 mg/mL warmed (4.85 mM)
DMSO Insoluble
体内 从左到右依次将纯溶剂加入产品,现配现用:
10% DMSO+30% PEG 300+5% Tween 80+ddH2O
1mg/mL

* 溶解度检测是由Selleck技术部门检测的,可能会和文献中提供的溶解度有所差异,这是由于生产工艺和批次不同产生的正常现象。请按照顺序依次加入各个纯溶剂。

化学数据

分子量 411.62
化学式

C27H41NO2

CAS号 4449-51-8
稳定性 powder
别名 11-deoxojervine

计算器

摩尔浓度计算器

摩尔浓度计算器

本计算器可帮助您计算出特定溶液中溶质的质量、溶液浓度和体积之间的关系,公式为:

质量 (g) = 浓度 (mol/L) x 体积 (L) x 分子量 (g/mol)

摩尔浓度计算公式

  • 质量
    浓度
    体积
    分子量

*在配置溶液时,请务必参考Selleck产品标签上、MSDS / COA(可在Selleck的产品页面获得)批次特异的分子量使用本工具。

稀释计算器

稀释计算器

用本工具协助配置特定浓度的溶液,使用的计算公式为:

开始浓度 x 开始体积 = 最终浓度 x 最终体积

稀释公式

稀释公式一般简略地表示为: C1V1 = C2V2 ( 输入 输出 )

  • C1
    V1
    C2
    V2

在配置溶液时,请务必参考Selleck产品标签上、MSDS / COA(可在Selleck的产品页面获得)批次特异的分子量使用本工具。.

连续稀释计算器方程

  • 连续稀释

  • 计算结果

  • C1=C0/X C1: LOG(C1):
    C2=C1/X C2: LOG(C2):
    C3=C2/X C3: LOG(C3):
    C4=C3/X C4: LOG(C4):
    C5=C4/X C5: LOG(C5):
    C6=C5/X C6: LOG(C6):
    C7=C6/X C7: LOG(C7):
    C8=C7/X C8: LOG(C8):
分子量计算器

分子量计算器

通过输入化合物的化学式来计算其分子量:

总分子量:g/mol

注:化学分子式大小写敏感。C10H16N2O2 c10h16n2o2

摩尔浓度计算器

质量 浓度 体积 分子量
计算

技术支持

在订购、运输、储存和使用我们的产品的任何阶段,您遇到的任何问题,均可以通过拨打我们的热线电话400-668-6834,或者技术支持邮箱tech@selleck.cn,直接联系到我们。我们会在24小时内尽快联系您。

操作手册

如果有其他问题,请给我们留言。

  • * 必填项

常见问题及建议解决方法

  • 问题 1:

    How to reconstitute the compound for in vivo use in mice?

  • 回答:

    One paper dissolved this drug in DMSO, and diluted in saline: Berman DM, et al. Nature, 2003, 425(6960), 846-851. Alternatively, you can try this vehicle: 10% DMSO+30% PEG 300+5% Tween 80+ddH2O for P.O. When preparing the solution, please dissolve the compound in DMSO clearly first. Then add PEG300 and Tween, after they mixed well, dilute with water.

Hedgehog/Smoothened Signaling Pathway Map

Hedgehog/Smoothened Inhibitors with Unique Features

相关Hedgehog/Smoothened产品

Tags: 购买Cyclopamine | Cyclopamine供应商 | 采购Cyclopamine | Cyclopamine价格 | Cyclopamine生产 | 订购Cyclopamine | Cyclopamine代理商
×
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID